» Articles » PMID: 37444417

The Regulation of M6A Modification in Glioblastoma: Functional Mechanisms and Therapeutic Approaches

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Jul 14
PMID 37444417
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma is the most prevalent primary brain tumour and invariably confers a poor prognosis. The immense intra-tumoral heterogeneity of glioblastoma and its ability to rapidly develop treatment resistance are key barriers to successful therapy. As such, there is an urgent need for the greater understanding of the tumour biology in order to guide the development of novel therapeutics in this field. N6-methyladenosine (m6A) is the most abundant of the RNA modifications in eukaryotes. Studies have demonstrated that the regulation of this RNA modification is altered in glioblastoma and may serve to regulate diverse mechanisms including glioma stem-cell self-renewal, tumorigenesis, invasion and treatment evasion. However, the precise mechanisms by which m6A modifications exert their functional effects are poorly understood. This review summarises the evidence for the disordered regulation of m6A in glioblastoma and discusses the downstream functional effects of m6A modification on RNA fate. The wide-ranging biological consequences of m6A modification raises the hope that novel cancer therapies can be targeted against this mechanism.

Citing Articles

Trends and frontiers of RNA methylation in cancer over the past 10 years: a bibliometric and visual analysis.

Liu B, Gao X, Piao Y Front Genet. 2024; 15:1461386.

PMID: 39473440 PMC: 11519982. DOI: 10.3389/fgene.2024.1461386.


Influence of RNA Methylation on Cancerous Cells: A Prospective Approach for Alteration of In Vivo Cellular Composition.

Rupareliya M, Shende P Adv Exp Med Biol. 2024; 1474():79-103.

PMID: 39259424 DOI: 10.1007/5584_2024_820.


Emerging role of m6A modification in ovarian cancer: progression, drug resistance, and therapeutic prospects.

Alam S, Giri P Front Oncol. 2024; 14:1366223.

PMID: 38544837 PMC: 10966408. DOI: 10.3389/fonc.2024.1366223.

References
1.
Zaccara S, Ries R, Jaffrey S . Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019; 20(10):608-624. DOI: 10.1038/s41580-019-0168-5. View

2.
Gimple R, Yang K, Halbert M, Agnihotri S, Rich J . Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity. Nat Rev Cancer. 2022; 22(9):497-514. DOI: 10.1038/s41568-022-00486-x. View

3.
Huff S, Kummetha I, Zhang L, Wang L, Bray W, Yin J . Rational Design and Optimization of mA-RNA Demethylase FTO Inhibitors as Anticancer Agents. J Med Chem. 2022; 65(16):10920-10937. PMC: 9421652. DOI: 10.1021/acs.jmedchem.1c02075. View

4.
Rodriguez H, Zenklusen J, Staudt L, Doroshow J, Lowy D . The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. Cell. 2021; 184(7):1661-1670. PMC: 8459793. DOI: 10.1016/j.cell.2021.02.055. View

5.
Couturier C, Ayyadhury S, Le P, Nadaf J, Monlong J, Riva G . Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nat Commun. 2020; 11(1):3406. PMC: 7343844. DOI: 10.1038/s41467-020-17186-5. View